Mochida Pharmaceutical Co.,Ltd. (4534) Stock Price

Mochida Pharmaceutical has two main business segments: pharmaceuticals and healthcare. In the pharmaceutical business, Mochida Pharmaceutical outsources drug manufacturing to Mochida Pharmaceutical Factory Co., Ltd., and purchases and sells those products. The company also procures and sells products from Mochida Pharmaceutical Sales Co., Ltd.

Some pharmaceutical products are procured by Mochida Pharmaceutical Sales Co., Ltd. from Mochida Pharmaceutical and then sold to the market. Additionally, Mochida Pharmaceutical Factory Co., Ltd. outsources some pharmaceutical manufacturing to Techno Fine Co., Ltd. Techno Net Co., Ltd. handles real estate brokerage and building management services, which Mochida Pharmaceutical also outsources.

In the healthcare business, subsidiary Mochida Healthcare Co., Ltd. outsources healthcare product manufacturing to Mochida Pharmaceutical Factory Co., Ltd., and purchases and sells those products. Through these operations, Mochida Pharmaceutical serves the market in both pharmaceuticals and healthcare products.

Mochida Pharmaceutical has established a long-term vision to "grow as a distinctive life and health-related company group that is recognized for its value globally by meeting medical and healthcare needs." To realize this vision, the company launched the "22-24 Medium-Term Management Plan" starting in 2022, focusing on innovation creation and productivity improvement.

From fiscal year 2025, Mochida Pharmaceutical will implement the "25-27 Medium-Term Management Plan," positioning it as "three years of accelerated growth strategy." The plan prioritizes strengthening profitability of core businesses, continued investment in growth businesses, and reinforcement of management foundations. In particular, the pharmaceutical business will maximize the value of new drugs and expand biosimilar offerings, while the healthcare business will focus on brand establishment and sales network optimization.

Additionally, Mochida Pharmaceutical is actively investing in biomaterials, nucleic acid therapeutics, and cell therapeutics, aiming for early commercialization. The company is also committed to global expansion and strengthening its presence in overseas markets. Through these initiatives, Mochida Pharmaceutical is pursuing sustainable growth and advancing toward achieving its 2031 targets.